Gilead Sciences' (GILD) Remdesivir Sparks Market Hope With Trial Success
Gilead's COVID-19 treatment shows efficacy in Phase 3 trial, NIAID study

Gilead Sciences (GILD, $78.67) reprised its goal as one of Wall Street's most-watched health care stocks on Wednesday after announcing positive results from trials for its COVID-19 treatment remdesivir.
Gilead announced that its COVID-19 treatment remdesivir met its primary endpoint in a National Institute of Allergy and Infectious Diseases (NIAID) clinical study. It also provided encouraging data from an open-label Phase 3 trial.
The Phase 3 trial focused on severely ill patients and found similar results for those who took five- or 10-day dosing durations, with "more than half of patients in both treatment groups (being) discharged from the hospital by Day 14."

Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
"The study demonstrates the potential for some patients to be treated with a 5-day regimen, which could significantly expand the number of patients who could be treated with our current supply of remdesivir," Gilead Chief Medical Officer Merdad Parsey said in a release. "This is particularly important in the setting of a pandemic, to help hospitals and healthcare workers treat more patients in urgent need of care."
Later Wednesday, the U.S. Food and Drug Administration said it was in "sustained and ongoing" discussions with the drugmaker over making its COVID-19 treatment available "as quickly as possible, as appropriate." The New York Times reported that a senior administration official said remdesivir could get FDA authorization for emergency use as soon as today.
GILD stock, which has climbed 21% through April 28, versus an 11% loss for the S&P 500, was up 9% in premarket action after a trading halt for the pending news. The company's stock has climbed in 2020 amid hopes that remdesivir – which Gilead introduced years ago as a general antiviral and was previously tested as an Ebola treatment – would prove effective against the COVID-19 coronavirus.
However, the drug is of interest to more than just GILD shareholders.
Because of its potential, the broader stock market has occasionally ebbed and flowed on any shreds of information about remdesivir's performance in clinical trials. Indeed, stock-market index futures surged higher ahead of Wednesday's open following Gilead's reports.
Remdesivir was touted early as a possible game-changer in the world's battle against COVID-19. "There's only one drug right now that we think may have real efficacy. And that's remdesivir," Bruce Aylward, an international leader of the World Health Organization's joint mission to China, said Feb. 24.
The market jumped April 16 amid a STAT News report claiming success against COVID-19 in a Chicago hospital. However, stocks broadly receded April 23 after the WHO accidentally published draft documents outlining a disappointing Chinese trial – documents that Gilead said included "inappropriate characterizations of the study."
Kyle Woodley is the Editor-in-Chief of Young and The Invested, a site dedicated to improving the personal finances and financial literacy of parents and children. He also writes the weekly The Weekend Tea newsletter, which covers both news and analysis about spending, saving, investing, the economy and more.
Kyle was previously the Senior Investing Editor for Kiplinger.com, and the Managing Editor for InvestorPlace.com before that. His work has appeared in several outlets, including Yahoo! Finance, MSN Money, Barchart, The Globe & Mail and the Nasdaq. He also has appeared as a guest on Fox Business Network and Money Radio, among other shows and podcasts, and he has been quoted in several outlets, including MarketWatch, Vice and Univision. He is a proud graduate of The Ohio State University, where he earned a BA in journalism.
You can check out his thoughts on the markets (and more) at @KyleWoodley.
-
Stock Market Today: Stocks Give Back GDP Gains After Beige Book
The latest GDP report showed the U.S. economy grew at a rapid-fire rate in the third quarter, but the Fed's Beige Book sparked concerns.
By Karee Venema Published
-
How Charlie Munger Helped Create Berkshire Hathaway, and Warren Buffett
Munger's passing reminds us that Berkshire Hathaway is much more than the value of its stock holdings.
By Dan Burrows Published
-
Stock Market Today: Stocks Give Back GDP Gains After Beige Book
The latest GDP report showed the U.S. economy grew at a rapid-fire rate in the third quarter, but the Fed's Beige Book sparked concerns.
By Karee Venema Published
-
Stock Market Today: Stocks Struggle for Direction After Mixed Fed Messages
E-commerce platform PDD Holdings jumped after earnings, while rival Shein reportedly filed confidential IPO paperwork.
By Karee Venema Published
-
Stock Market Today: Stocks Close Lower on Cyber Monday
The main indexes were choppy to start the week, though several e-commerce stocks jumped on encouraging online holiday shopping numbers.
By Karee Venema Published
-
Stock Market Today: Stocks Keep Their Weekly Win Streak Alive
The main indexes closed mixed Friday, though all three nabbed a fourth straight weekly gain.
By Karee Venema Published
-
Stock Market Today: Stocks Resume Their Winning Ways
The major benchmarks rebounded from a rare down session to post broad-based gains Wednesday.
By Dan Burrows Published
-
Stock Market Today: Stocks Close Lower After Fed Minutes, Retail Earnings
Burlington was a big winner on the earnings front, while Kohl's slumped after its results.
By Karee Venema Published
-
Stock Market Today: Microsoft Gains Boost Stock Market
The blue chip stock popped on news the software giant has snagged OpenAI's ousted CEO to help lead an advanced AI research team.
By Karee Venema Published
-
Stock Market Today: Stocks Extend Weekly Win Streak Ahead of Thanksgiving
Although the main indexes were quiet to end the week, Gap stock soared after the retailer reported earnings.
By Karee Venema Published